Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.
By K. Hara, Y. Maruki, Samuel Long, K. Yoshino, N. Oshiro, Sujuti Hidayat, C. Tokunaga, J. Avruch, K. Yonezawa. Cell, 2002
1,893 citations recorded by the source corpus.
mTOR controls cell growth, in part by regulating p70 S6 kinase alpha (p70alpha) and eukaryotic initiation factor 4E binding protein 1 (4EBP1). Raptor is a 150 kDa mTOR binding protein that also binds 4EBP1 and p70alpha. The binding of raptor to mTOR is necessary for the mTOR-catalyzed phosphorylation of 4EBP1 in vitro, and it strongly enhances the mTOR kinase activity toward p70alpha. Rapamycin or amino acid withdrawal increases, whereas insulin strongly inhibits, the recovery of 4EBP1 and raptor on 7-methyl-GTP Sepharose. Partial inhibition of raptor expression by RNA interference (RNAi) reduces mTOR-catalyzed 4EBP1 phosphorylation in vitro. RNAi of C. elegans raptor yields an array of phenotypes that closely resemble those produced by inactivation of Ce-TOR. Thus, raptor is an essential scaffold for the mTOR-catalyzed phosphorylation of 4EBP1 and mediates TOR action in vivo.
Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Toxicology
View Paper: https://www.semanticscholar.org/paper/801201a77daca0ae1093b802ec96cd7e3344e380
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
In Molecular Biology
- David M. Sabatini
- M. Laplante
- Michael N. Hall
- K. Guan
- R. A. Saxton
- J. Blenis
- Young Chul Kim
- Nahum Sonenberg
In Toxicology
Citations in the corpus
- mTOR and cancer: insights into a complex relationship (2006, positive): “, which is a component of mTORC1 that can recruit substrates to the mTOR kinase domai”
- mTOR signaling at a glance (2009, background): “It has been proposed that Raptor might affect mTORC1 activity by regulating assembly of the complex and by recruiting substrates for mTOR ( Hara et al., 2002; Kim et al., 2002).”
- Dysregulation of the TSC-mTOR pathway in human disease (2004, background): “In mammalian cells, mTOR also forms both mTORC1 and mTORC2 (refs”
- The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span (2004, background): “It is specifically inhibited by the macrolide rapamycin, which forms a complex with the prolyl isomerase FKBP12 to interact with TOR (Heitman et al., 1991; Stan et al., 1994; Chen et al., 1995; Choi et al., 1996).”
- Defining the role of mTOR in cancer. (2007, background): “Nearly a decade after the discovery of mTOR, researchers found that mTOR nucleates a rapamycinand nutrient-sensitive multiprotein complex (now called mTORC1) (Hara et al., 2002; Kim et al., 2002; Loewith et al., 2002).”
- The nuts and bolts of AGC protein kinases (2010, background): “S6K isoforms are phosphorylated at their hydrophobic motif (on Thr389) by mTORC1, which comprises mTOR , regulatory associated protein of mTOR ( RAPTOR ) and mLST8 (Ref”
- mTOR: a pharmacologic target for autophagy regulation. (2015, positive): “On the other hand, RAPTOR and PRAS40 are specific to mTORC1 (6–11) whereas RICTOR, mSin1, and PROCTOR1/2 are specific to mTORC2 (10, 12–16).”
- Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. (2008, background): “TORC1 is comprised of mTOR, Raptor, and G L (Hara et al. 2002; Kim et al. 2002, 2003), while TORC2 is comprised of mTOR, Rictor, and G L (Sarbassov et al.”
- GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. (2003, methodology): “Hara et al. (2002) independentlymediated signaling to S6K1, a downstream effector of identified the same interacting protein and adopted themTOR, and in the control of cell size.”
- mTOR Signaling in Growth, Metabolism, and Disease. (2017, background): “1B, Kim et al. 2002; Hara et al. 2002; Kim et al. 2003).”
- mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. (2013, background): “mTOR forms two distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), which differ in their composition, downstream targets, regulation, and sensitivity to the allosteric inhibitor rapamycin (Hara et al., 2002; Kim et al., 2002; Sarbassov et al., 2004).”